<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33994783</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1178-2005</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>International journal of chronic obstructive pulmonary disease</Title><ISOAbbreviation>Int J Chron Obstruct Pulmon Dis</ISOAbbreviation></Journal><ArticleTitle>Incidence and Prognostic Factors of Respiratory Viral Infections in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease.</ArticleTitle><Pagination><StartPage>1265</StartPage><EndPage>1273</EndPage><MedlinePgn>1265-1273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/COPD.S306916</ELocationID><Abstract><AbstractText Label="PURPOSE">Severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) that require hospitalization and emergency department visits are associated with considerable morbidity and mortality. Respiratory viral infection is an important cause of severe AECOPD. We evaluated the incidence and prognostic factors of viral infection in severe AECOPD.</AbstractText><AbstractText Label="PATIENTS AND METHODS">We performed a retrospective study of 262 cases of severe AECOPD in 192 patients who required hospitalization and emergency department visits at a tertiary teaching hospital in Daegu, Korea. A multiplex polymerase chain reaction panel using a nasopharyngeal swab sample was performed to detect viral infection.</AbstractText><AbstractText Label="RESULTS">Viral infection was detected in 108 events (41.2%) from 96 patients. The most common virus was rhinovirus/enterovirus (27.5%), followed by influenza virus (22.5%), respiratory syncytial virus (13.3%), parainfluenza virus (12.5%), coronavirus (12.5%), metapneumovirus (7.5%), and adenovirus (4.2%). Virus-positive exacerbations, compared to virus-negative exacerbations, had a higher frequency of symptoms of rhinopharyngitis, higher neutrophil count and C-reactive protein (CRP) level, and lower eosinophil count. Multivariate analysis demonstrated that elevated CRP levels (odds ratio [OR], 2.76; 95% confidence interval [CI], 1.24-6.15), symptoms of rhinopharyngitis (OR, 1.98; 95% CI, 1.03-3.78), low eosinophil count (OR, 1.74; 95% CI, 1.03-2.92), and inhaled corticosteroid (ICS) use (OR, 1.70; 95% CI 1.04-2.80) were associated with viral infection in severe AECOPD.</AbstractText><AbstractText Label="CONCLUSION">The incidence of viral infection in severe AECOPD was 41.2%, and the most commonly detected virus was rhinovirus/enterovirus. Increased CRP level, symptoms of rhinopharyngitis, low eosinophil count, and use of ICS were associated with viral infection in severe AECOPD.</AbstractText><CopyrightInformation>&#xa9; 2021 Jang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Jong Geol</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0001-8040-5363</Identifier><AffiliationInfo><Affiliation>Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>June Hong</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-7104-8325</Identifier><AffiliationInfo><Affiliation>Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hyun Jung</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Int J Chron Obstruct Pulmon Dis</MedlineTA><NlmUniqueID>101273481</NlmUniqueID><ISSNLinking>1176-9106</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="Y">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="N">exacerbation</Keyword><Keyword MajorTopicYN="N">multiplex polymerase chain reaction</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">viral infection</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>17</Day><Hour>5</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33994783</ArticleId><ArticleId IdType="pmc">PMC8112874</ArticleId><ArticleId IdType="doi">10.2147/COPD.S306916</ArticleId><ArticleId IdType="pii">306916</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557&#x2013;582. doi:10.1164/rccm.201701-0218PP</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201701-0218PP</ArticleId><ArticleId IdType="pubmed">28128970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030442</ArticleId><ArticleId IdType="pmc">PMC1664601</ArticleId><ArticleId IdType="pubmed">17132052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786&#x2013;796. doi:10.1016/s0140-6736(07)61382-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(07)61382-8</ArticleId><ArticleId IdType="pmc">PMC7134993</ArticleId><ArticleId IdType="pubmed">17765528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324&#x2013;330. doi:10.1164/rccm.201605-1014OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201605-1014OC</ArticleId><ArticleId IdType="pmc">PMC5328181</ArticleId><ArticleId IdType="pubmed">27556408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662&#x2013;671. doi:10.1164/rccm.201104-0597OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201104-0597OC</ArticleId><ArticleId IdType="pubmed">21680942</ArticleId></ArticleIdList></Reference><Reference><Citation>Boixeda R, Rabella N, Sauca G, et al. Microbiological study of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and the usefulness of analytical and clinical parameters in its identification (VIRAE study). Int J Chron Obstruct Pulmon Dis. 2012;7:327&#x2013;335. doi:10.2147/copd.S30568</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/copd.S30568</ArticleId><ArticleId IdType="pmc">PMC3379868</ArticleId><ArticleId IdType="pubmed">22745532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58(1):37&#x2013;42. doi:10.1136/thorax.58.1.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thorax.58.1.37</ArticleId><ArticleId IdType="pmc">PMC1746460</ArticleId><ArticleId IdType="pubmed">12511718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15(3):536&#x2013;542. doi:10.1111/j.1440-1843.2010.01722.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1843.2010.01722.x</ArticleId><ArticleId IdType="pmc">PMC7192224</ArticleId><ArticleId IdType="pubmed">20415983</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Oh JY, Lee YS, et al. Bacterial and viral identification rate in acute exacerbation of chronic obstructive pulmonary disease in Korea. Yonsei Med J. 2019;60(2):216&#x2013;222. doi:10.3349/ymj.2019.60.2.216</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2019.60.2.216</ArticleId><ArticleId IdType="pmc">PMC6342712</ArticleId><ArticleId IdType="pubmed">30666844</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015;45(1):76&#x2013;86. doi:10.1183/09031936.00092214</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00092214</ArticleId><ArticleId IdType="pubmed">25186260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak HJ, Park DW, Kim JE, et al. Prevalence and risk factors of respiratory viral infections in exacerbations of chronic obstructive pulmonary disease. Tohoku J Exp Med. 2016;240(2):131&#x2013;139. doi:10.1620/tjem.240.131</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.240.131</ArticleId><ArticleId IdType="pubmed">27725531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5Suppl 2):398s&#x2013;401s. doi:10.1378/chest.117.5_suppl_2.398s</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.117.5_suppl_2.398s</ArticleId><ArticleId IdType="pubmed">10843984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kherad O, Kaiser L, Bridevaux PO, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896&#x2013;904. doi:10.1378/chest.09-2225</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-2225</ArticleId><ArticleId IdType="pmc">PMC7094578</ArticleId><ArticleId IdType="pubmed">20435659</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus TE, Marley A-M, Baxter N, et al. Respiratory viral infection in exacerbations of COPD. Respir Med. 2008;102(11):1575&#x2013;1580. doi:10.1016/j.rmed.2008.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2008.06.006</ArticleId><ArticleId IdType="pmc">PMC7125807</ArticleId><ArticleId IdType="pubmed">18672353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwaans WA, Mallia P, van Winden ME, Rohde GG. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease&#x2014;a systematic review. J Clin Virol. 2014;61(2):181&#x2013;188. doi:10.1016/j.jcv.2014.06.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2014.06.025</ArticleId><ArticleId IdType="pmc">PMC7106508</ArticleId><ArticleId IdType="pubmed">25066886</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarinejad H, Moghoofei M, Mostafaei S, Salimian J, Azimzadeh Jamalkandi S, Ahmadi A. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb Pathog. 2017;113:190&#x2013;196. doi:10.1016/j.micpath.2017.10.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2017.10.021</ArticleId><ArticleId IdType="pmc">PMC7127529</ArticleId><ArticleId IdType="pubmed">29038056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko FW, Ip M, Chan PK, et al. Viral etiology of acute exacerbations of COPD in Hong Kong. Chest. 2007;132(3):900&#x2013;908. doi:10.1378/chest.07-0530</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.07-0530</ArticleId><ArticleId IdType="pmc">PMC7094736</ArticleId><ArticleId IdType="pubmed">17573516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158&#x2013;174. doi:10.1177/1753465815618113</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753465815618113</ArticleId><ArticleId IdType="pmc">PMC5933560</ArticleId><ArticleId IdType="pubmed">26611907</ArticleId></ArticleIdList></Reference><Reference><Citation>Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618&#x2013;1623. doi:10.1164/ajrccm.164.9.2105011</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.164.9.2105011</ArticleId><ArticleId IdType="pubmed">11719299</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus TE, Marley AM, Baxter N, et al. Respiratory viral infection in exacerbations of COPD. Respir Med. 2008;102(11):1575&#x2013;1580. doi:10.1016/j.rmed.2008.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2008.06.006</ArticleId><ArticleId IdType="pmc">PMC7125807</ArticleId><ArticleId IdType="pubmed">18672353</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin T, Zhu Z, Mei Z, et al. Analysis of viral infection and biomarkers in patients with acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J. 2018;12(3):1228&#x2013;1239. doi:10.1111/crj.12656</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.12656</ArticleId><ArticleId IdType="pmc">PMC7162408</ArticleId><ArticleId IdType="pubmed">28586150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini SS, Ghasemian E, Jamaati H, Tabaraie B, Amini Z, Cox K. Association between respiratory viruses and exacerbation of COPD: a case-control study. Infect Dis (Lond). 2015;47(8):523&#x2013;529. doi:10.3109/23744235.2015.1022873</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/23744235.2015.1022873</ArticleId><ArticleId IdType="pubmed">25800059</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749&#x2013;1759. doi:10.1056/NEJMoa043951</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043951</ArticleId><ArticleId IdType="pubmed">15858184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamelin ME, C&#xf4;t&#xf9; S, Laforge J, et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clinical Infectious Diseases. 2005;41(4):498&#x2013;502. doi:10.1086/431981</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/431981</ArticleId><ArticleId IdType="pubmed">16028158</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancardi E, Fennell M, Rawlinson W, Thomas PS. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Intern Med J. 2016;46(10):1160&#x2013;1165. doi:10.1111/imj.13213</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.13213</ArticleId><ArticleId IdType="pmc">PMC7165870</ArticleId><ArticleId IdType="pubmed">27515577</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353&#x2013;2361. doi:10.1001/jama.2013.5732</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.5732</ArticleId><ArticleId IdType="pubmed">23757083</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis m, and prevention of chronic obstructive pulmonary disease. 2020. Available from:
www.goldcopd.org/. Accessed April30, 2021.</Citation></Reference><Reference><Citation>Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(6):1286&#x2013;1297. doi:10.1378/chest.13-2137</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.13-2137</ArticleId><ArticleId IdType="pubmed">24504044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162&#x2013;166. doi:10.1164/rccm.200611-1630OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200611-1630OC</ArticleId><ArticleId IdType="pubmed">17400730</ArticleId></ArticleIdList></Reference><Reference><Citation>Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775&#x2013;789. doi:10.1056/NEJMoa063070</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa063070</ArticleId><ArticleId IdType="pubmed">17314337</ArticleId></ArticleIdList></Reference><Reference><Citation>Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine. 2007;356(8):775&#x2013;789. doi:10.1056/NEJMoa063070</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa063070</ArticleId><ArticleId IdType="pubmed">17314337</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep. 2014;4:7176. doi:10.1038/srep07176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07176</ArticleId><ArticleId IdType="pmc">PMC5384105</ArticleId><ArticleId IdType="pubmed">25417801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan MC, Yeung YC, Yu ELM, Yu WC, Eosinophil B. Risk of exacerbation in chronic obstructive pulmonary disease patients: a retrospective cohort analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2869&#x2013;2877. doi:10.2147/copd.S268018</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/copd.S268018</ArticleId><ArticleId IdType="pmc">PMC7667703</ArticleId><ArticleId IdType="pubmed">33204083</ArticleId></ArticleIdList></Reference><Reference><Citation>Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965&#x2013;974. doi:10.1164/rccm.201509-1869OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201509-1869OC</ArticleId><ArticleId IdType="pubmed">26641631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. The Lancet Respiratory Medicine. 2015;3(6):435&#x2013;442. doi:10.1016/S2213-2600(15)00106-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(15)00106-X</ArticleId><ArticleId IdType="pubmed">25878028</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest. 2019;156(1):92&#x2013;100. doi:10.1016/j.chest.2019.02.406</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.02.406</ArticleId><ArticleId IdType="pubmed">30978330</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake MG, Bivins-Smith ER, Proskocil BJ, et al. Human and mouse eosinophils have antiviral activity against parainfluenza virus. Am J Respir Cell Mol Biol. 2016;55(3):387&#x2013;394. doi:10.1165/rcmb.2015-0405OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2015-0405OC</ArticleId><ArticleId IdType="pmc">PMC5023029</ArticleId><ArticleId IdType="pubmed">27049514</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani JS, Njoku CM, Bereznicki B, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(156):190166. doi:10.1183/16000617.0166-2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0166-2019</ArticleId><ArticleId IdType="pmc">PMC9488450</ArticleId><ArticleId IdType="pubmed">32499306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst JR, Donaldson GC, Wilkinson TMA, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J. 2005;26(5):846&#x2013;852. doi:10.1183/09031936.05.00043405</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.05.00043405</ArticleId><ArticleId IdType="pubmed">16264045</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Oh JY, Lee YS, et al. Pseudomonas aeruginosa infection increases the readmission rate of COPD patients. Int J Chronic Obstruct Pulmonary Dis. 2018;13:3077&#x2013;3083. doi:10.2147/COPD.S173759</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S173759</ArticleId><ArticleId IdType="pmc">PMC6174684</ArticleId><ArticleId IdType="pubmed">30323578</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>